mFluiDx presents a fast and portal DNA-based technology for identifyuing outbreaks of dangerous diseases in the field. Using microfluidics, they’ve engineered a field-ready, affordable, sensitive, and rapid approach that democratizes high-need diagnostics for everyone in the world.

mFluiDx selected as one of the top 20 startups to pitch at TechCrunch Startup Battlefield, from a pool of 900 startups globally.

The company is dedicated to empower scientists to study and isolate cells at high resolution via sensitive, robust, and multiplexed RNA detection in both fixed and live cells. Their CRISPR based RNA detection reagents will plug seamlessly into existing flow cytometry workflows, reducing the time and cost-basis of research and development. Their kits and reagents can supercharge the many applicaitons based on fixed-cell analysis and live-cell sorting with wide-ranging implications for detection of disease to design of biomarkers and drugs.

They are currently engaged in a clinical stufy for their NAC, and beginning development of enhanced biologically derived grafts — capable of sustained drug delivery — to improve outcomes for third degree burn survivors through an NIH grant.

Bioreactors technology is very different when you’re optimizing for one reaction at one liter versus 100,000 liters, but this is where Stämm comes in. They are reinventing the way bioreactors work by developing a modular microfluidic platform that controls all the physical parameters, such as nutrients and dissolved oxygen, in a controlled environment. Unlike traditional bioreactor systems, their microfluidic bioreactor scales by adding more modules to increase the size of the reactor.

Sun Genomics found that an individual’s genome can help identify which probiotic strains are best for the person. By creating personalized probiotics, the company can eliminate the guesswork that’s involved with buying probiotics off the shelf and help people regain control of their health. Customers of all ages (babies, tots, adults) can get a whole genome sequencing of their gut microflora now, and get custom-tailored probiotics sent to their door right away, with the Floré product by Sun Genomics.

Sun Genomics has also launched a new academic collaboration focused on understanding the potential link between the gut microbiome and the Autism Spectrum Disorder

Caspr has been acquired by a Fortune 100 company. Now Caspr is using their special Cas to develop cheap and rapid CRISPR-based test kits ƒor infectious diseases. One month after they graduated from IndieBio, COVID-19 hit and Caspr’s team knew exactly what they had to do. They flew out their scientists out of Argentina to come live in San Francisco, where 15 of them lived in a single house in Alamo Square, all trying to develop tests for the coronavirus.

After demonstrating how rapidly they were able to develop their tests, Caspr was approached by Amazon to help with their internal efforts to test their employees.

This data rich platform has applications for human health, from discovering novel biomarkers to developing new clinical tests to drug development. Our vision is to create a single low cost liquid biopsy that can be used for early detection across a wide range of common and rare diseases and conditions. Dalton is also working with many Fortune 500 companies to understand and develop better food and consumer goods, and optimize bioprocesses for industry.

When time is of the essence, being able to screen potential therapies with your personalized cancer avatar in under 10 days is fast. Doing so with more accuracy than today’s sequencing or organoid approaches is huge. Through their growing list of strategic partnerships, OncoPrecision is screening, selecting, and speeding up the delivery of precision oncology.